NBTK.DE vs. ARKG
Compare and contrast key facts about Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) and ARK Genomic Revolution Multi-Sector ETF (ARKG).
NBTK.DE and ARKG are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. NBTK.DE is a passively managed fund by Invesco that tracks the performance of the Nasdaq Biotechnology. It was launched on Nov 6, 2014. ARKG is an actively managed fund by ARK. It was launched on Oct 31, 2014.
Performance
NBTK.DE vs. ARKG - Performance Comparison
Loading graphics...
NBTK.DE vs. ARKG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
NBTK.DE Invesco Nasdaq Biotech UCITS ETF | 3.68% | 18.60% | 4.57% | 2.51% | -6.11% | 7.46% | 14.59% | 17.24% |
ARKG ARK Genomic Revolution Multi-Sector ETF | -5.05% | 8.44% | -23.50% | 12.74% | -51.05% | -28.98% | 157.29% | 18.40% |
Different Trading Currencies
NBTK.DE is traded in EUR, while ARKG is traded in USD. To make them comparable, the ARKG values have been converted to EUR using the latest available exchange rates.
Returns By Period
In the year-to-date period, NBTK.DE achieves a 3.68% return, which is significantly higher than ARKG's -5.05% return.
NBTK.DE
- 1D
- 1.59%
- 1M
- -0.49%
- YTD
- 3.68%
- 6M
- 18.68%
- 1Y
- 30.13%
- 3Y*
- 10.80%
- 5Y*
- 4.98%
- 10Y*
- —
ARKG
- 1D
- 2.43%
- 1M
- -8.48%
- YTD
- -5.05%
- 6M
- -4.77%
- 1Y
- 25.13%
- 3Y*
- -5.48%
- 5Y*
- -20.88%
- 10Y*
- 4.79%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
NBTK.DE vs. ARKG - Expense Ratio Comparison
NBTK.DE has a 0.40% expense ratio, which is lower than ARKG's 0.75% expense ratio.
Return for Risk
NBTK.DE vs. ARKG — Risk / Return Rank
NBTK.DE
ARKG
NBTK.DE vs. ARKG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NBTK.DE | ARKG | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.34 | 0.56 | +0.78 |
Sortino ratioReturn per unit of downside risk | 1.85 | 1.10 | +0.75 |
Omega ratioGain probability vs. loss probability | 1.24 | 1.13 | +0.12 |
Calmar ratioReturn relative to maximum drawdown | 2.53 | 0.86 | +1.67 |
Martin ratioReturn relative to average drawdown | 10.98 | 2.20 | +8.79 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| NBTK.DE | ARKG | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.34 | 0.56 | +0.78 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.24 | -0.48 | +0.72 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.12 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.42 | 0.10 | +0.32 |
Correlation
The correlation between NBTK.DE and ARKG is 0.50, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
NBTK.DE vs. ARKG - Dividend Comparison
Neither NBTK.DE nor ARKG has paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NBTK.DE Invesco Nasdaq Biotech UCITS ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 0.82% | 1.34% |
Drawdowns
NBTK.DE vs. ARKG - Drawdown Comparison
The maximum NBTK.DE drawdown since its inception was -30.99%, smaller than the maximum ARKG drawdown of -81.91%. Use the drawdown chart below to compare losses from any high point for NBTK.DE and ARKG.
Loading graphics...
Drawdown Indicators
| NBTK.DE | ARKG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -30.99% | -83.59% | +52.60% |
Max Drawdown (1Y)Largest decline over 1 year | -15.66% | -27.51% | +11.85% |
Max Drawdown (5Y)Largest decline over 5 years | -30.99% | -80.18% | +49.19% |
Max Drawdown (10Y)Largest decline over 10 years | — | -83.59% | — |
Current DrawdownCurrent decline from peak | -1.01% | -75.76% | +74.75% |
Average DrawdownAverage peak-to-trough decline | -10.84% | -35.32% | +24.48% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.89% | 10.24% | -7.35% |
Volatility
NBTK.DE vs. ARKG - Volatility Comparison
The current volatility for Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) is 6.72%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 12.19%. This indicates that NBTK.DE experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| NBTK.DE | ARKG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.72% | 12.19% | -5.47% |
Volatility (6M)Calculated over the trailing 6-month period | 14.08% | 31.44% | -17.36% |
Volatility (1Y)Calculated over the trailing 1-year period | 22.45% | 45.15% | -22.70% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.44% | 44.08% | -23.64% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.10% | 40.48% | -18.38% |